Regeneron Pharmaceuticals, Inc. (REGN) earnings
REGN earnings moved a median of +1.21% by the close. Quarterly and annual REGN reports and results, each read against the price at its own news timestamp. Back to the REGN overview →
17 measured REGN earnings events.
Where these REGN earnings landedvs 17 measured REGN earnings reactions
| Middle 50% of REGN earnings reactions | -1.97% to +5.09% |
|---|---|
| Median reaction (to close) | +1.21% |
| Measured reactions | 17 |
Point-in-time · zero look-ahead
Half of the 17 REGN earnings events with a measured close landed between -1.97% and +5.09%; 65% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026 | Press release | -1.41% | -1.97% | |
| Form 10-Q REGENERON PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | +0.12% | +5.48% | |
| Regeneron Reports Second Quarter 2026 Financial and Operating Results | Press release | +0.12% | +5.48% | |
| Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast | Press release | +1.14% | +1.49% | |
| Form 10-Q REGENERON PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | -0.36% | -2.37% | |
| Regeneron Reports First Quarter 2026 Financial and Operating Results | Press release | -0.36% | -2.37% | |
| Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026 | Press release | +0.45% | +0.98% | |
| Form 10-K REGENERON PHARMACEUTICAL For: Dec 31 | SEC filing · Form 10-K | +1.01% | +1.21% | |
| Form 10-Q REGENERON PHARMACEUTICAL For: Sep 30 | SEC filing · Form 10-Q | +0.03% | +6.94% | |
| Regeneron Reports Third Quarter 2025 Financial and Operating Results | Press release | +0.03% | +6.94% | |
| Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025 | Press release | +1.82% | +5.09% | |
| Form 10-Q REGENERON PHARMACEUTICAL For: Jun 30 | SEC filing · Form 10-Q | -1.59% | -4.14% | |
| Regeneron Reports Second Quarter 2025 Financial and Operating Results | Press release | -1.59% | -4.14% | |
| Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 | Press release | +0.33% | -0.15% | |
| Form 10-Q REGENERON PHARMACEUTICAL For: Mar 31 | SEC filing · Form 10-Q | -1.95% | +1.27% | |
| Regeneron Reports First Quarter 2025 Financial and Operating Results | Press release | -1.95% | +1.27% | |
| Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025 | Press release | -0.68% | +0.95% |
Keep exploring
More REGN: analyst actions → · SEC filings → · REGN overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DexCom, Inc. (DXCM) | 2,000+ | +0.04% | 51% |
| Endo International plc - Ordinary Shares (ENDP) | 2,000+ | 0.00% | 49% |
| Novo Nordisk A/S (NVO) | 1,909 | 0.00% | 50% |
| CELGENE (CELG) | 1,880 | +0.03% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.